NRAS and cancer: At individual mutation levels, we identified pan-cancer and cancer specific associations between specific driver mutations and cell type iScores, that may partially explain resistance mechanisms activated by tumors such as escape from immune surveillance (e.g., CASP8) or immune exclusion (e.g., NRAS).